Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme Myozyme revised PDUFA date

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Genzyme's Pompe disease treatment Myozyme (alglucosidase alfa) has a revised user fee date of April 28 following FDA's 90-day extension. The extension is to provide time to review additional agency-requested information, Genzyme says. The company submitted the BLA July 28 (1Pharmaceutical Approvals Monthly August 2005, In Brief); the enzyme replacement therapy is receiving a priority review...

You may also be interested in...

Genzyme Myozyme BLA

Genzyme expects a priority review for its Myozyme (alglucosidase alfa) BLA for treatment of Pompe disease. The company submitted the application July 28, setting a priority review action date at Jan. 28. Pompe disease, which the firm estimates affects fewer than 10,000 people worldwide, is part of the same family of lysosomal storage disorders as mucopolysaccharidosis, Fabry and Gaucher disease...

Siegfried Reaches ‘Next Level’ As Sales And Profits Lift

Swiss company Siegfried has seen an increase in sales, EBITDA and net profit in 2020 and expects its turnover to exceed CHF1bn this year. The firm is also looking to execute on its partnership with BioNTech on filling and packaging the firm’s COVID-19 vaccine.

COVID-19 Tests: How The EU Rules Are Changing And Where Questions Still Lie

There are very few regulatory hurdles to placing a COVID-19 test on the EU market under the IVD Directive. This situation, however, is changing under the IVD Regulation. The European Commission explains what manufacturers need to weigh up when deciding their regulatory pathway.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts